ANI Pharmaceuticals
ANIP
208 hedge funds and large institutions have $1.14B invested in ANI Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 88 increasing their positions, 43 reducing their positions, and 30 closing their positions.
105% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 43
27% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 30
18% more capital invested
Capital invested by funds: $962M → $1.14B (+$177M)
17.87% more ownership
Funds ownership: 72.1% → 89.96% (+18%)
3% more funds holding
Funds holding: 201 → 208 (+7)
9% less call options, than puts
Call options by funds: $721K | Put options by funds: $793K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$38.2M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$34.5M |
| 3 |
JP Morgan Chase
New York
|
+$20.8M |
| 4 |
Millennium Management
New York
|
+$18.3M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$16.4M |
Top Sellers
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$33.4M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
-$8.36M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.63M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$5.54M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$4.96M |
ANIP Hedge Fund Activity: Q3 2024 in Review
208 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2024, worth a combined $1.14B — up 18% from $962M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ANIP positions and 30 closed out — a net gain of 8 holders — while 88 added to existing stakes and 43 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $38.2M. The largest seller was Rubric Capital Management (New York), cutting an estimated $33.4M.
- 208 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2024, up from 201 in Q2 2024.
- Funds reported $1.14B of ANI Pharmaceuticals stock for Q3 2024, up 18% quarter-over-quarter.
- 38 funds opened new ANI Pharmaceuticals positions in Q3 2024 and 30 closed out, a net change of +8 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2024 was Goldman Sachs, an estimated $38.2M added.
- The largest ANI Pharmaceuticals seller in Q3 2024 was Rubric Capital Management (New York), an estimated $33.4M sold.
Based on aggregated 13F filings for Q3 2024.